These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 1369474)
21. Clinical implications of multidrug resistance to chemotherapy. de Vries EG; Pinedo HM Cancer Treat Res; 1991; 57():171-86. PubMed ID: 1686716 [No Abstract] [Full Text] [Related]
22. P glycoprotein (P-gp) and drug resistance--time for reappraisal? Kaye SB Br J Cancer; 1993 Apr; 67(4):641-3. PubMed ID: 8097103 [No Abstract] [Full Text] [Related]
23. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA. Dietel M; Herzig I; Reymann A; Brandt I; Schaefer B; Bunge A; Heidebrecht HJ; Seidel A J Cancer Res Clin Oncol; 1994; 120(5):263-71. PubMed ID: 7907333 [TBL] [Abstract][Full Text] [Related]
27. Is the multidrug transporter a flippase? Higgins CF; Gottesman MM Trends Biochem Sci; 1992 Jan; 17(1):18-21. PubMed ID: 1374941 [TBL] [Abstract][Full Text] [Related]
28. Multidrug resistance and P-glycoprotein expression in human cancer. Ma DD; Bell DR Aust N Z J Med; 1989 Dec; 19(6):736-43. PubMed ID: 2576624 [No Abstract] [Full Text] [Related]
30. Detection of multidrug-resistant protein, P-glycoprotein in childhood leukaemia and lymphoma. Mizuno Y; Hara T; Nagata M; Tawa A; Tsuruo T; Ueda K Eur J Pediatr; 1991 Apr; 150(6):416-8. PubMed ID: 1674913 [TBL] [Abstract][Full Text] [Related]
31. Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type. Reichle A; Diddens H; Altmayr F; Rastetter J; Andreesen R Cancer Chemother Pharmacol; 1994; 34(4):307-16. PubMed ID: 7913420 [TBL] [Abstract][Full Text] [Related]
32. AACR special conference in cancer research. Membrane transport in multidrug resistance, development, and disease. American Association for Cancer Research. D'Incalci M; Broxterman HJ; van Kalken CK Ann Oncol; 1991 Oct; 2(9):635-9. PubMed ID: 1683789 [No Abstract] [Full Text] [Related]
33. Antineoplastic drug resistance and breast cancer. Morrow CS; Cowan KH Ann N Y Acad Sci; 1993 Nov; 698():289-312. PubMed ID: 7904140 [No Abstract] [Full Text] [Related]
34. Molecular mechanisms of drug resistance. Hayes JD; Wolf CR Biochem J; 1990 Dec; 272(2):281-95. PubMed ID: 1980062 [No Abstract] [Full Text] [Related]
35. Multidrug resistance and P-glycoprotein expression. Ling V Ann N Y Acad Sci; 1987; 507():7-8. PubMed ID: 2894794 [No Abstract] [Full Text] [Related]
36. Analysis of the mechanism of resistance of 7 novel MDR variants. Redmond A; Moran E; Clynes M Biochem Soc Trans; 1992 Feb; 20(1):57S. PubMed ID: 1353036 [No Abstract] [Full Text] [Related]
37. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Sanfilippo O; Ronchi E; De Marco C; Di Fronzo G; Silvestrini R Eur J Cancer; 1991; 27(2):155-8. PubMed ID: 1673852 [TBL] [Abstract][Full Text] [Related]
38. Specificity of immunohistochemical expression of P-glycoprotein. Battifora H Hum Pathol; 1991 May; 22(5):506-7. PubMed ID: 1674494 [No Abstract] [Full Text] [Related]
39. Multidrug resistance from the clinical point of view. van Kalken CK; Pinedo HM; Giaccone G Eur J Cancer; 1991; 27(11):1481-6. PubMed ID: 1683777 [No Abstract] [Full Text] [Related]
40. The clinical relevance of multidrug resistance. Bellamy WT; Dalton WS; Dorr RT Cancer Invest; 1990; 8(5):547-62. PubMed ID: 1979932 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]